ArticleEuropean urology open science2025
Radical Prostatectomy Combined with Prostate Specific Membrane Antigen-radioguided Lymph Node Dissection is Associated with Longer Treatment-free Survival for Patients with Primary Lymph Node-positive Prostate Cancer.
Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Surgical Management of PSMA PET-Positive Lymph Nodes in Prostate Cancer.Current urology reports · 2026Review
- Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: The optimal treatment for patients with prostate cancer with primary lymph node metastases (LNMs) is still a matter of debate. Radical prostatectomy (RP) combined with prostate-specific membrane antigen (PSMA)-radioguided surgery (RGS) may be a helpful technique in removal of LNMs detected on preoperative PSMA positron emission tomography (PET) in comparison to conventional lymph node dissection (LND). The aim of our retrospective analysis was to determine whether addition of PSMA-RGS at primary radical prostatectomy (RP) is associated with longer survival. Methods: Key findings and limitations: Matched samples were created for a cohort comprising 46 patients who underwent RP with RGS, and 42 patients who underwent RP without RGS, with matching according to LNM distribution, number of LNMs on preoperative PSMA PET scans, and surgical margin status. Multivariate Cox regression revealed an association between longer treatment-free survival (TFS) and PSMA RGS (hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.30-0.94). A higher number of positive lymph nodes (HR 1.29, 95% CI 1.07-1.56) and positive surgical margins (HR 1.86, 95% CI 1.06-3.25) were associated with shorter TFS. The main limitations are the retrospective design and small sample size. Conclusions and clinical implications: Addition of PSMA-RGS at primary RP was associated with longer TFS for patients with limited PSMA PET-positive locoregional LNMs. Patient summary: We looked at whether a technique to label and detect lymph node metastases during prostate cancer surgery is linked to better cancer control for patients whose preoperative scans showed limited spread to the lymph nodes. We found that this approach may lead to better cancer control after surgery and a longer time before additional treatment is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.